SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.
| 説明 | SRI-011381, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease. |
| In vitro | SRI-11381 is neuroprotective. SRI-011381 promote fibrillar Aβ clearance by macrophages, as demonstrated by the dose-dependent decreases of Aβ in the conditioned medium derived from compound-treated macrophages. |
| In vivo | SRI-011381 protects mice against kainic acid-induced excitotoxicity and neurodegeneration. SRI-011381 (30 mg/kg, dissolved in DMSO) is injected (i.p.) into the SBE-luc mice. SRI-011381 is rapidly absorbed after oral administration to FBV mice with an oral bioavailability of approximately 50%. SRI-011381 by oral gavage of 10, 30, and 75 mg/kg for 14 days resulted in significant changes in hematological endpoints, most notably reductions in red blood cells, hematocrit and hemoglobin. SRI-011381 reduces neurodegeneratio in APP751Lon, Swetransgenic mice. |
| 別名 | SRI-011381 hydrochloride [1629138-41-5(free base)] |
| 分子量 | 365.94 |
| 分子式 | C20H32ClN3O |
| CAS No. | 2070014-88-7 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 12 mg/mL (32.79 mM)
H2O: 76.92 mg/mL (210 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
参考文献
投与量変換You can also refer to dose conversion for different animals. 詳細
In vivo投与量計算 (透明溶液)計算器bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SRI-011381 hydrochloride 2070014-88-7 Stem Cells TGF-beta/Smad SRI 011381 hydrochloride multiple Transforming growth factor beta sclerosis α-SMA NALP3 SRI 011381 collagen-1 SRI-011381 inhibit SRI-011381 hydrochloride [1629138-41-5(free base)] TGF-β neuroprotective SRI011381 Inhibitor SRI011381 hydrochloride inhibitor
